Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer

10617 Background: Whether trastuzumab should be continued after tumor progression remains unknown.We describe the activity of successive trastuzumab-containing regimens in patients with HER2-overex...